SCHEMBL31494763

CC(C)C[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)O)[C@@H](C)O

nearest known ligand 0.59

Predicted protein targets (top 9)

	gene	UniProt	supporting neighbours	confidence
▸	ERAP2	Q6P179	5/20	0.59

▸	IL1RN	P18510	4/20	0.53

▸	ERAP1	Q9NZ08	3/20	0.53

▸	MAGI3	Q5TCQ9	1/20	0.53

▸	IL23R	Q5VWK5	4/20	0.51

▸	TLR2	O60603	3/20	0.51

▸	KISS1R	Q969F8	3/20	0.50

▸	GHSR	Q92847	1/20	0.50

▸	GLP1R	P43220	2/20	0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL31632761	0.93	ERAP2 (0.61)	ERAP2IL1RNERAP1MAGI3IL23R
SCHEMBL30204843	0.90	GLP1R (0.55)	ERAP2IL23RTLR2KISS1RGHSR
SCHEMBL29973374	0.88	GHSR (0.63)	ERAP2IL1RNERAP1KISS1RGHSR
SCHEMBL30065757	0.87	ERAP2 (0.65)	ERAP2IL1RNERAP1MAGI3KISS1R
SCHEMBL28081223	0.86	ERAP2 (0.58)	ERAP2TLR2KISS1RGLP1R
SCHEMBL28081101	0.86	GLP1R (0.58)	ERAP2TLR2GLP1R
SCHEMBL31465165	0.85	MAGI3 (0.53)	ERAP2MAGI3IL23RGHSRGLP1R
SCHEMBL30262173	0.85	ERAP2 (0.56)	ERAP2MAGI3IL23RTLR2KISS1R
SCHEMBL31597621	0.85	ERAP2 (0.56)	ERAP2IL1RNERAP1MAGI3IL23R
SCHEMBL29855839	0.85	ERAP2 (0.60)	ERAP2IL1RNERAP1MAGI3TLR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
WO-2025056677-A1	DASIGLUCAGON FOR USE IN THE TREATMENT OF CONGENITAL HYPERINSULINISM	ZEALAND PHARMA A/S (DK)	2025-03-20	—	—	WO	disclosed